LOGIN  |  REGISTER
Terns Pharmaceuticals
Cue Biopharma

Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2024 on Monday, November 4, 2024

October 04, 2024 | Last Trade: US$71.65 0.89 1.26

MARLBOROUGH, Mass. / Oct 04, 2024 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the fourth quarter of fiscal 2024 on Monday, November 4, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.

Interested participants may listen to the call by dialing (888) 394-8218 (in the United States and Canada) or +1 (773) 305-6853 (for international callers) and referencing access code 4567924. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins.

Hologic will provide a live and webcast replay of the call on the Company’s website at www.investors.hologic.com. The call will be available there for 30 days. The webcast replay will be available approximately two hours after the call ends.

About Hologic

Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.

Terns Pharmaceuticals

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB